Shopify Inc. vs TransMedics Group Inc — how do they compare? Shopify Inc. trades at $127.02 (market cap $163.13B), while TransMedics Group Inc trades at $86.4 (market cap $3.00B). The key difference: Shopify Inc. is far larger — about 54.4× TransMedics Group Inc's market cap, and Shopify Inc. is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| SHOP | TMDX | |
|---|---|---|
Market Cap | $163.13B | $3.00B |
Sector | Technology | Technology |
52-Week High | $179.01 | $150.42 |
52-Week Low | $95.40 | $61.99 |
Enterprise Value | $158.36B | $3.39B |
Signals from Pluang's Aura AI — not financial advice
SHOP trades at $134.1, down 7.57% in the past 24 hours, reflecting recent market pressure. The stock is near its 52-week low of $130.00, with technical indicators showing a bearish trend. Fundamentally, revenue grew to $11.56B in 2025, but the P/E ratio of 90.61 suggests a premium valuation. Recent news highlights AI initiatives and competitive comparisons, while earnings show mixed quarterly results with a miss in Q4 2025 but beats in Q1 and Q2 2026.
Outlook: Strong revenue growth and expanding gross merchandise volume support long-term potential, but high valuation and recent price decline pose near-term risks. Analyst consensus is bullish with a $167.50 price target, though competitive pressures and market volatility require careful monitoring for investors.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Trailing returns across standard periods
Latest headlines on both assets
Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →